Drug product formulations exert a crucial role in determining the magnitude of drug bioavailability. Bioavailability refers to the fraction of an administered dose that reaches the systemic circulation in an active form. Optimizing formulations can significantly improve this process, leading to more effective drug delivery and therapeutic outcomes.

Eli Lilly and Company has become a key player in the manufacturing of tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant ability to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepatide requires a series of precision steps to ensure